Wednesday, October 15, 2025
Distribution: (800) 510 0384
Washington DC
New York
Toronto
Press ID  
  • Login
The Hudson Weekly
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity
No Result
View All Result
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity
No Result
View All Result
The Hudson Weekly
No Result
View All Result

FDA Approves Treatment for Chronic Kidney Disease

Approval is First to Cover Many Causes of Disease

Craig Richer by Craig Richer
May 3, 2021
in Health
A A
Share on FacebookShare on Twitter

U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression.

“Chronic kidney disease is an important public health issue, and there is a significant unmet need for therapies that slow disease progression and improve outcomes,” said Aliza Thompson, M.D., M.S., deputy director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research. “Today’s approval of Farxiga for the treatment of chronic kidney disease is an important step forward in helping people living with kidney disease.”

HudsonNewsroom

Hezi Badnany: A Global Healer Bringing Ancient Energy Medicine to Modern New York

The Best Ways to Stay Healthy With a Busy Family

Kratom, 7-OH, and the Courage of Radical Transparency

Chronic kidney disease occurs when the kidneys are damaged and cannot filter blood normally. Due to this defective filtering, patients can have complications related to fluid, electrolytes (minerals required for many bodily processes), and waste build-up in the body. Chronic kidney disease sometimes can progress to kidney failure. Patients also are at high risk of cardiovascular disease, including heart disease and stroke.

The efficacy of Farxiga to improve kidney outcomes and reduce cardiovascular death in patients with chronic kidney disease was evaluated in a multicenter, double-blind study. In this study, 4,304 patients were randomly assigned to receive either Farxiga or a placebo. The study compared the two groups for the number of patients whose disease progressed to a composite (or combined) endpoint that included at least a 50% reduction in kidney function, progression to kidney failure, or cardiovascular or kidney death. Results showed that 197 of the 2,152 patients who received Farxiga had at least one of the composite endpoint events compared to 312 of the 2,152 patients who received a placebo. The study also compared the two groups for the number of patients who were hospitalized for heart failure or died from cardiovascular disease. A total of 100 patients who received Farxiga were hospitalized or died compared to 138 patients who received a placebo.

Farxiga was not studied, nor is expected to be effective, in treating chronic kidney disease among patients with autosomal dominant or recessive polycystic (characterized by multiple cysts) kidney disease or among patients who require or have recently used immunosuppressive therapy to treat kidney disease.

Patients should not use Farxiga if they have a history of serious hypersensitivity reactions to the medication or if they are on dialysis treatment. Serious, life-threatening cases of Fournier’s Gangrene have occurred in patients with diabetes taking Farxiga. Patients should consider a lower dose of insulin or insulin secretagogue to reduce the risk of hypoglycemia (low blood sugar) if they are also taking Farxiga. Farxiga can cause dehydration, serious urinary tract infections, genital yeast infections, and metabolic acidosis or ketoacidosis (acid build-up in the blood). Patients should be assessed for their volume status and kidney function before starting Farxiga.

Farxiga was originally approved in 2014 to improve glycemic control in adults with type 2 diabetes in addition to diet and exercise.

Farxiga received Fast Track, Breakthrough Therapy, and Priority Review designations for the indication being approved today. Fast track is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Breakthrough therapy designation is designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s). Priority review directs overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis or prevention of serious conditions when compared to standard applications.

The FDA granted the approval of Farxiga to AstraZeneca.

Craig Richer

Craig Richer

Newsroom Editor

More from HW Newsdesk

Hezi Badnany: A Global Healer Bringing Ancient Energy Medicine to Modern New York
Health

Hezi Badnany: A Global Healer Bringing Ancient Energy Medicine to Modern New York

October 8, 2025
The Best Ways to Stay Healthy With a Busy Family
Health

The Best Ways to Stay Healthy With a Busy Family

September 30, 2025
Kratom, 7-OH, and the Courage of Radical Transparency
Health

Kratom, 7-OH, and the Courage of Radical Transparency

September 16, 2025

HW Newsroom

IP Protection for MVPs and Early-Stage Products
Technology

IP Protection for MVPs and Early-Stage Products

by Sylvia MacIntyre
October 8, 2025

Launching a Minimum Viable Product (MVP) is a bold, strategic step for most startups. It’s designed to move fast, test...

Hezi Badnany: A Global Healer Bringing Ancient Energy Medicine to Modern New York

Hezi Badnany: A Global Healer Bringing Ancient Energy Medicine to Modern New York

October 8, 2025
The Future of Lashes: How Tatiana Kisliuk Is Leading the Lift Movement

The Future of Lashes: How Tatiana Kisliuk Is Leading the Lift Movement

October 8, 2025
How to Sell a Business Without Regrets: Avoid These Common Mistakes

Why Website Design and SEO Must Work Together

October 7, 2025
Exploring the World of Live Casino Gaming

All About Golden Crown Casino for Australian Players: A Detailed Guide

October 7, 2025
Brief Introduction to BananaBotcrypto

Brief Introduction to BananaBotcrypto

October 7, 2025
Gulf Coast Western Reviews Show Consistent Partner Retention Through Transparent Energy Investment Approach

Gulf Coast Western Reviews Show Consistent Partner Retention Through Transparent Energy Investment Approach

October 6, 2025
Top 10 Book Ghostwriting Services

Top 10 Book Ghostwriting Services

October 5, 2025
Special Occasion Dresses That Steal the Spotlight

Special Occasion Dresses That Steal the Spotlight

October 4, 2025
The Difference Between Car and Truck Accident Claims

The Difference Between Car and Truck Accident Claims

October 3, 2025
The Naginata: From Samurai Battlefield to Women's Art

The Naginata: From Samurai Battlefield to Women’s Art

October 2, 2025
The ABCs of Live Casinos: How to Approach Them Like a Savant

The ABCs of Live Casinos: How to Approach Them Like a Savant

October 2, 2025
No Result
View All Result

Headlines

The Architect of AI’s New Language: A Conversation With Boris Kriuk

Common Problems in Flender Gearboxes and How to Diagnose Them

The 5G Shift: How Next-Gen Connectivity Is Redefining Live Casino Gaming

IP Protection for MVPs and Early-Stage Products

Hezi Badnany: A Global Healer Bringing Ancient Energy Medicine to Modern New York

The Future of Lashes: How Tatiana Kisliuk Is Leading the Lift Movement

Trending

Generational Wealth Planning: Balfour Capital Group’s Global Perspective
Financial

Generational Wealth Planning: Balfour Capital Group’s Global Perspective

by Michelle Kellett
October 10, 2025

Balfour Capital Group views generational wealth as more than numbers on a balance sheet. It is the...

Booz Demands His Due - A Gritty Look Inside ‘What About Booz?’

Booz Demands His Due – A Gritty Look Inside ‘What About Booz?’

October 10, 2025
The Architect of AI's New Language: A Conversation With Boris Kriuk

The Architect of AI’s New Language: A Conversation With Boris Kriuk

October 10, 2025
Common Problems in Flender Gearboxes and How to Diagnose Them

Common Problems in Flender Gearboxes and How to Diagnose Them

October 9, 2025
The 5G Shift: How Next-Gen Connectivity Is Redefining Live Casino Gaming

The 5G Shift: How Next-Gen Connectivity Is Redefining Live Casino Gaming

October 9, 2025
  • Booz Demands His Due – A Gritty Look Inside ‘What About Booz?’

https://hudsonweekly.com/booz-demands-his-due-a-gritty-look-inside-what-about-booz/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost #music #newmusic
  • The Architect of AI’s New Language: A Conversation With Boris Kriuk

https://hudsonweekly.com/the-architect-of-ais-new-language-a-conversation-with-boris-kriuk/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost #ai #tech
  • Overflow Expands Tap-to-Give Feature With More Flexible NFC Engagement for Churches

https://marketsherald.com/overflow-expands-tap-to-give-feature-with-more-flexible-nfc-engagement-for-churches/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost #church #donation
  • Sensi.AI Secures $45 Million Series C Funding to Drive Care Innovation for Seniors

https://lincolncitizen.com/sensi-ai-secures-45-million-series-c-funding-to-drive-care-innovation-for-seniors/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • AMC Health Appoints Alan Petrazzi as Executive VP of Government Division to Drive Telehealth Innovations

https://lincolncitizen.com/amc-health-appoints-alan-petrazzi-as-executive-vp-of-government-division-to-drive-telehealth-innovations/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost #telehealth #health
  • CareChoice Wins Outstanding Growth Award for Excellence in Home Care Services

https://belmontstar.com/carechoice-wins-outstanding-growth-award-for-excellence-in-home-care-services/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost
  • BP Defence Launches Bullet-Resistant Backpacks for Enhanced Student Safety

https://belmontstar.com/bp-defence-launches-bullet-resistant-backpacks-for-enhanced-student-safety/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost #backback #bulletproof
  • NexCore Group Breaks Ground on Two Innovative Senior Living Communities in Denver and North Bethesda

https://fairmontpost.com/nexcore-group-breaks-ground-on-two-innovative-senior-living-communities-in-denver-and-north-bethesda/

#nyc #losangeles #chicago #houston #phoenix #philadelphia #sandiego #dallas #sanfrancisco #seattle #denver #washingtondc #boston #detroit #vancouver #toronto #publicrelations #marketingagency #earnedmedia #editorial #marketing #guestpost #guestposting #sponsored #sponsoredpost

© 2025 The Hudson Weekly. Published by The Ritz Herald. Editions: Markets Herald • Lincoln Citizen • Madison Graph • Belmont Star • Fairmont Post

Address: 1177 6th Avenue, 5th Floor, New York, NY 10036. Removals: pr@hudsonweekly.com. Phone: (718) 313-5252. M-F: 9AM-5PM. Privacy Policy

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

No Result
View All Result
  • Financial
  • Blockchain
  • Technology
  • Entertainment
  • Lifestyle
  • Arts
  • Health
  • Sports
  • Cybersecurity

© 2025. The Hudson Weekly